Background. Granulocyte‐monocyte apheresis has been proposed for the treatment of
ulcerative colitis, although it is limited by costs and variability of results. Aim. To assess …

The etiology of inflammatory bowel disease (IBD) is not completely understood, thus current
therapies have been empirical and directed at treating symptoms rather than addressing the …

Refractory ulcerative colitis that fails conventional intense medical treatment often leads to
colectomy. Although ciclosporin and infliximab may avert colectomy in certain cases, these …

Objective. Selective leukocyte apheresis is a new type of non-pharmacological treatment for
patients with active ulcerative colitis and Crohn's disease. Preliminary data have indicated …

Leukocytes are thought to play an important role in the pathogenesis of inflammatory bowel
diseases; granulocyte–monocyte adsorptive (GMA) apheresis, an extracorporeal technique …

Background Patients with UC and CD, characterized by elevations in peripheral blood
granulocytes, monocytes/macrophages, and proinflammatory mediators, may benefit from …

Background/Aims: In patients with active ulcerative colitis (UC), pharmacologics, although
initially effective in most patients, are associated with refractoriness, loss of response or …

Background Apheresis therapy involves the selective removal of leukocytes and is used to
induce remission in ulcerative colitis (UC) patients. The aim of this study was to demonstrate …

Background Hitherto, therapeutic depletion of granulocytes and monocytes by adsorption
(GMA) has been associated with significant and insignificant efficacy in patients with …

Background Elderly ulcerative colitis (UC) is increasing. Elderly UC differ from younger UC
with respect to the course of their disease. Granulocyte adsorption apheresis (CAP) is often …